Rejane Mattar,Daniel Ferraz de Campos Mazo,Flair José Carrilho
Rejane Mattar
Most people are born with the ability to digest lactose, the major carbohydrate in milk and the main source of nutrition until weaning. Approximately 75% of the world's population loses this ability at some point, while others can digest la...
Giulia Fiorini,Angelo Zullo,Luigi Gatta et al.
Giulia Fiorini et al.
Helicobacter pylori infection remains widespread internationally, with a definite morbidity and mortality. The efficacy of standard 7-14 day triple therapies is decreasing, mainly due to increasing primary bacterial resistance to antibiotic...
Barrier effect of Esoxx(®) on esophageal mucosal damage: experimental study on ex-vivo swine model [0.03%]
Esoxx(®)对食管黏膜损伤屏障作用的实验研究-离体猪模型试验
Massimo P Di Simone,Fabio Baldi,Valentina Vasina et al.
Massimo P Di Simone et al.
The aim of the present study was to assess the potential barrier effect of Esoxx(®), a new nonprescription medication under development for the relief of gastroesophageal reflux symptoms. Esoxx is based on a mixture of hyaluronic acid and ...
Is long-lasting mucosal elevation the only valid parameter when evaluating a lifting agent? [0.03%]
评估提拉剂功效的唯一有效参数是长期黏膜抬高吗？
Stefano Pontone,Simone Manfredelli,Dimitri Krizzuk et al.
Stefano Pontone et al.
Targeted therapies for diarrhea-predominant irritable bowel syndrome [0.03%]
腹泻为主 Irritable Bowel Syndrome的靶向治疗
Kevin W Olden
Kevin W Olden
Irritable bowel syndrome (IBS) causes gastrointestinal symptoms such as abdominal pain, bloating, and bowel pattern abnormalities, which compromise patients' daily functioning. Common therapies address one or two IBS symptoms, while others ...
Efficacy of esomeprazole in treating acid-related diseases in Japanese populations [0.03%]
艾司奥美拉唑治疗日本人的酸相关性疾病有效性研究
Mitsushige Sugimoto,Takahisa Furuta
Mitsushige Sugimoto
Esomeprazole (Nexium(®); AstraZeneca), the S-isomer of omeprazole, is the first proton pump inhibitor (PPI) to be developed as an optical isomer. Compared with omeprazole, esomeprazole has an improved pharmacokinetic profile with regards t...
Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells [0.03%]
明胶鞣酸盐可降低脂多糖对人肠上皮细胞的促炎作用
Giuseppina Frasca,Venera Cardile,Carmelo Puglia et al.
Giuseppina Frasca et al.
Background: Gelatin tannate is a mixture of tannic acid and gelatin. Tannic acid has astringent properties, due to its capacity to form protein-macromolecular complexes, as well as antibacterial and antioxidant properties...
Efficacy of submucosal injection of different solutions inclusive blood components on mucosa elevation for endoscopic resection [0.03%]
不同注射液包括血液成分抬举胃肠道黏膜的有效性研究
Oliver H Al-Taie,Yildiz Bauer,Christoph G Dietrich et al.
Oliver H Al-Taie et al.
Background: Endoscopic resection has become the standard treatment for noninvasive gastrointestinal malignancies. In flat mucosal tumors, normal saline is frequently used for submucosal fluid injection in order to reduce ...
Giuseppe Gagliardi,Monica Goswami,Roberto Passera et al.
Giuseppe Gagliardi et al.
Introduction: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis...
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori [0.03%]
根除幽门螺杆菌非铋四联（伴同）疗法研究进展
Javier P Gisbert,Xavier Calvet
Javier P Gisbert
Background: Traditional standard triple therapy for Helicobacter pylori (H. pylori) infection (proton pump inhibitor-clarithromycin-amoxicillin) can easily be converted to non-bismuth quadruple (concomitant) therapy by th...